Search

Your search keyword '"Baeck, Marie"' showing total 501 results
Start Over Author "Baeck, Marie"
501 results on '"Baeck, Marie"'

7. Corticosteroids

Author

Baeck, Marie, Goossens, An, Bircher, Andreas J., editor, Maibach, Howard I., editor, Brockow, Knut, editor, and Barbaud, Annick, editor

Published
2022
Full Text
View/download PDF

12. Belgian atopic dermatitis guidelines

Author

Lapeere, Hilde, primary, Speeckaert, Reinhart, additional, Baeck, Marie, additional, Dezfoulian, Bita, additional, Lambert, Julien, additional, Roquet-Gravy, Pierre-Paul, additional, Stockman, Annelies, additional, White, Jonathan, additional, Castelijns, Francisca, additional, and Gutermuth, Jan, additional

Published
2023
Full Text
View/download PDF

13. Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real‐life multicentric observational study

Author

De Greef, Axel, primary, Ghislain, Pierre‐Dominique, additional, de Montjoye, Laurence, additional, Adriaenssens, Kristel, additional, Bulinckx, Audrey, additional, Colmant, Caroline, additional, Cuvelier, Marie, additional, Deleu, Hilde, additional, Goeteyn, Marleen, additional, Janssens, Pauline, additional, Kul, Anouschka, additional, Roquet‐Gravy, Charlotte, additional, Stragier, Ilse, additional, and Baeck, Marie, additional

Published
2023
Full Text
View/download PDF

18. Belgian atopic dermatitis guidelines.

Author

Lapeere, Hilde, Speeckaert, Reinhart, Baeck, Marie, Dezfoulian, Bita, Lambert, Julien, Roquet-Gravy, Pierre-Paul, Stockman, Annelies, White, Jonathan, Castelijns, Francisca, and Gutermuth, Jan

Published
2024
Full Text
View/download PDF

21. Treatment of congenital Langerhans cell histiocytosis with cobimetinib.

Author

Benjelloun, Ghita, Roquet‐Gravy, Charlotte, Marot, Liliane, Secco, Léo‐Paul, Roquet‐Gravy, Pierre‐Paul, Baeck, Marie, and Bulinckx, Audrey

Subjects
LANGERHANS-cell histiocytosis, MITOGEN-activated protein kinases, PROTEIN kinase inhibitors, DISEASE remission
Abstract

We report a case of congenital multisystem Langerhans cell histiocytosis with cutaneous and hematopoietic involvement. After the failure of first‐line (vinblastine and prednisolone) and second‐line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen‐activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real‐life multicentric observational study.

Author

De Greef, Axel, Ghislain, Pierre‐Dominique, de Montjoye, Laurence, Adriaenssens, Kristel, Bulinckx, Audrey, Colmant, Caroline, Cuvelier, Marie, Deleu, Hilde, Goeteyn, Marleen, Janssens, Pauline, Kul, Anouschka, Roquet‐Gravy, Charlotte, Stragier, Ilse, and Baeck, Marie

Subjects
ATOPIC dermatitis, ECZEMA, ALLERGIC conjunctivitis, TEENAGERS
Abstract

A real-life observational study was conducted to evaluate the effectiveness and safety of tralokinumab, a monoclonal antibody, in adolescents with severe atopic dermatitis (AD). The study included 14 adolescents who had failed previous treatments and were treated with tralokinumab for 12 to 16 weeks. The primary outcome was improvement in clinical scores, specifically the Eczema Area and Severity Index (EASI) and the Peak Pruritus Numerical Rating Scale (PP-NRS). The study found that tralokinumab was effective in improving EASI and PP-NRS scores in most patients, with 28.6% achieving an EASI 75 and 42.8% experiencing a four-point or higher reduction in PP-NRS. The most common adverse events were flare of AD and injection-site reactions. The study concluded that tralokinumab is effective and well-tolerated in adolescents with severe AD, but longer-term studies are needed. [Extracted from the article]

Published
2024
Full Text
View/download PDF

27. Innovations 2022 en dermatologie

Author

De Greef, Axel, Baeck, Marie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, UCL - (SLuc) Centre de l'allergie, and UCL - (SLuc) Centre de malformations vasculaires congénitales

Subjects
Janus kinase inhibitors, Dermatite atopique, Inhibiteurs de Janus kinase, Maladies inflammatoires, Vitiligo, Pelade, Alopecia areata, Sécurité, Inflammatory diseases, Safety, Atopic dermatitis
Abstract

L’arrivée des inhibiteurs de Janus-Kinase (JAKi) dans l’arsenal thérapeutique en dermatologie permet une évolution considérable de la prise en charge de certaines pathologies inflammatoires comme la dermatite atopique, ou les maladies auto-immunes comme la pelade (alopecia areata) ou le vitiligo. Le profil d’action large des JAKi au niveau du blocage des cytokines, bénéfique en termes d’efficacité, implique toutefois une certaine prudence au niveau du profil de sécurité de ce groupe de molécules. Cet article se veut faire le point sur les dernières données de sécurité des JAKi. Il en ressort qu’il est fondamental de distinguer le risque en fonction des populations traitées et des pathologies ciblées par ces molécules. La prudence reste de mise chez les patients âgés, les patients présentant des facteurs de risque cardiovasculaires incluant un tabagisme actif ou ancien conséquent, et les patients présentant des antécédents oncologiques.

Published
2023

29. Tralokinumab‐induced injection‐site reactions.

Author

De Greef, Axel and Baeck, Marie

Subjects
*INFORMED consent (Medical law), *DRUG side effects, *SUBCUTANEOUS injections, *TERMINATION of treatment, *MEDICAL research
Abstract

This article discusses the occurrence of injection-site reactions (ISR) in patients receiving tralokinumab, a medication used to treat moderate-to-severe atopic dermatitis. The prevalence of ISR with tralokinumab in real-life studies was higher than in clinical trials. The article presents a case study of a 17-year-old male who experienced pruritic and painful ISR after self-injections of tralokinumab. Skin biopsy and testing ruled out an allergic reaction and suggested that incorrect injection procedure may have been the cause. Educating the patient on the correct procedure resulted in a decrease in the frequency and intensity of ISR. [Extracted from the article]

Published
2024
Full Text
View/download PDF

38. Atopische dermatitis, een overzichtelijke opfrissing van de basisprincipes

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, Terrasson, Julie, Baeck, Marie, Gutermuth, Jan, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, Terrasson, Julie, Baeck, Marie, and Gutermuth, Jan

Published
2022

39. Dermatite atopique, un rappel clair des principes de base

Author

UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service de dermatologie, Terrasson, Julie, Baeck, Marie, Gutermuth, Jan, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service de dermatologie, Terrasson, Julie, Baeck, Marie, and Gutermuth, Jan

Published
2022

40. Pandemic chilblains: Are they SARS-CoV-2-related or not?

Author

UCL - (SLuc) Service de dermatologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, De Greef, Axel, Coulie, Pierre G., Baeck, Marie, UCL - (SLuc) Service de dermatologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, De Greef, Axel, Coulie, Pierre G., and Baeck, Marie

Abstract

The exact etiopathology of chilblains observed during the Coronavirus Disease 2019 (COVID-19) pandemic is still unclear. Initially, SARS-CoV-2 appeared as the obvious causing agent, but two years of various investigations have failed to convincingly support its direct implication. Most affected individuals have no detectable virus, no anti-SARS-CoV-2 antibodies and no symptoms of COVID-19. Analyses of skin biopsies similarly failed to unambiguously demonstrate presence of the virus or its genome. In a recent hypothesis, SARS-CoV-2 would cause the lesions before being promptly eliminated by unusually strong type I interferon responses. With others, we feel that environmental factors have not been sufficiently considered, in particular cold exposure related to unprecedented containment measures. The cause of pandemic chilblains remains a stimulating puzzle which warrants further investigation.

Published
2022

41. Cutaneous leishmaniasis due to : A therapeutic challenge.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/CTMA - Centre de technologies moléculaires appliquées (plate-forme technologique), UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Mengeot, Laura, Yombi, Jean Cyr, Baeck, Marie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/CTMA - Centre de technologies moléculaires appliquées (plate-forme technologique), UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Mengeot, Laura, Yombi, Jean Cyr, and Baeck, Marie

Abstract

Cutaneous leishmaniasis (CL) is a chronic infectious skin disease caused by a group of protozoan parasites of the Leishmania genus. Parasites are transmitted to humans via the bite of sandflies. Leishmania aethiopica, one of the most neglected species, is the main causative agent of CL in Ethiopia, with infection characterized by reduced sensitivity to conventional drugs. Although the incidence of imported cases of CL is increasing in nonendemic areas, L aethiopica is rarely reported in travelers. We report a case of localized CL due to L aethiopica in a Belgian traveler. [...]

Published
2022

42. Sporotrichoid distributed tuberculous panniculitis as a late complication of intravesical bacillus Calmette-Guérin (BCG) immunotherapy.

Author

UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Centre de l'allergie, Nielens, Nina, Marot, Liliane, Baeck, Marie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - (SLuc) Service d'anatomie pathologique, UCL - (SLuc) Centre de l'allergie, Nielens, Nina, Marot, Liliane, and Baeck, Marie

Abstract

An 82-year-old man presented with unilateral oedema of the right lower limb overlaid with multiple sporotrichoid distributed panniculitis lesions. These symptoms appeared in a context of immunodepression and were associated with significant weight loss and a deterioration in general condition. The patient's medical history, the histological findings, PCR testing, and bacterial culture led to a diagnosis of cutaneous tuberculosis due to Mycobacterium bovis. This infection occurred as a late complication of intravesical bacillus Calmette-Guérin (BCG) instillations that the patient had received as an adjunctive immunotherapy for bladder cancer. This is an unusual clinical presentation and aetiology of cutaneous tuberculosis. Indeed, the observed sporotrichoid pattern is uncommon for tuberculous mycobacteria. Moreover, the occurrence of tuberculous skin lesions after intravesical BCG instillations is extremely rare, with only a few cases described, and, to the authors' knowledge, none with such a clinical presentation. This case report suggests that a medical history of BCG immunotherapy should always be considered when assessing any infectious-type cutaneous lesions and that skin should be regarded as a possible late localization of infectious complications of this treatment.

Published
2022

43. Innovations 2021 en dermatologie

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Centre de malformations vasculaires congénitales, de Montjoye, Laurence, De Greef, Axel, Degraeuwe, Alexia, Harkemanne, Evelyne, Thirion, Romane, Nobile, Laura, Ghislain, Pierre-Dominique, Baeck, Marie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Centre de malformations vasculaires congénitales, de Montjoye, Laurence, De Greef, Axel, Degraeuwe, Alexia, Harkemanne, Evelyne, Thirion, Romane, Nobile, Laura, Ghislain, Pierre-Dominique, and Baeck, Marie

Published
2022

44. Re-emergence of allergic contact dermatitis from chlorphenesin.

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, Herman, Anne, de Montjoye, Laurence, Baeck, Marie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie, Herman, Anne, de Montjoye, Laurence, and Baeck, Marie

Abstract

Only a few cases of allergic contact dermatitis (ACD) from chlorphenesin have been reported and since 2015 no new cases have been published. We describe two additional cases of ACD from this preservative in cosmetics observed during late 2021. [...]

Published
2022

49. Cutaneous leishmaniasis due to : A therapeutic challenge

Author

Mengeot, Laura, Yombi, Jean Cyr, Baeck, Marie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/CTMA - Centre de technologies moléculaires appliquées (plate-forme technologique), UCL - SSS/IREC/SLUC - Pôle St.-Luc, and UCL - (SLuc) Service de médecine interne générale

Subjects
cutaneous leishmaniasis, ambisome, glucantime antimoniate, PDT, photodynamic therapy, CL, Leishmania aethiopica, posaconazole
Abstract

Cutaneous leishmaniasis (CL) is a chronic infectious skin disease caused by a group of protozoan parasites of the Leishmania genus. Parasites are transmitted to humans via the bite of sandflies. Leishmania aethiopica, one of the most neglected species, is the main causative agent of CL in Ethiopia, with infection characterized by reduced sensitivity to conventional drugs. Although the incidence of imported cases of CL is increasing in nonendemic areas, L aethiopica is rarely reported in travelers. We report a case of localized CL due to L aethiopica in a Belgian traveler. [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results